Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Minerva Neurosciences, Inc.

NASDAQ: NERV · Life Sciences · 3 alerts · CIK 1598646

Share price
$2.20Close, Nov 16
Market cap
$110M
Shares outstanding
49.84MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Minerva Neurosciences, Inc. filings on SEC EDGAR ↗

4:01 PM ET 10-Q
Financial Results

Minerva Neurosciences Q3 2026 Results: Turns Profitable, Net Income $101M

Minerva Neurosciences reported a net income of $100.7 million for the third quarter of 2026, primarily driven by a $109.6 million non-cash gain from the change in fair value of warrant liabilities. However, the company experienced a net loss of $7.2 million for the nine months ended September 30, 2026, as research and development expenses surged to $17.6 million compared to $3.6 million in the prior year.

Key figure
Net income $101M
9:11 AM ET 8-K
Financial Results

Minerva Neurosciences Financial Results

Minerva Neurosciences reported third quarter 2026 financial results and provided a business update on its ongoing Phase 3 trial (C19 Study) of roluperidone for negative symptoms of schizophrenia. The company expects topline efficacy data from Phase A of the trial in the second half of 2027 and remains focused on developing non-dopaminergic treatments for CNS disorders.

Term
Q3 2026

“The psychiatry field has increasingly recognized the importance of finding non-dopaminergic mechanisms in the treatment of schizophrenia, particularly for negative symptoms. Roluperidone is the only late-stage candidate targeting negative symptoms directly. The C19 study, our ongoing Phase 3 trial, is designed to confirm the effect we saw in our prior trials. We remain focused on execution and on track for topline efficacy data in the second half of 2027.”

Remy Luthringer, Ph.D., Chief Executive Officer of Minerva Neurosciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.